You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
FAQ
Education
Download
About us
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsDetails

先聲藥業(02096.HK)注射用SIM0237新適應症臨床試驗獲批

阿思達克 10-17 00:46
先聲藥業(02096.HK)公布，集團自主研發的抗PD-L1/IL-15雙特異性抗體注射用SIM0237新適應症獲中國國家藥品監督管理局簽發藥物臨床試驗批准通知書，擬用於非肌層浸潤性膀胱癌患者。
先聲藥業(02096.HK)
Relevant Stocks
先聲藥業(02096.HK)
Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
Contact Us
Customer Service Hotline︰+852 3018 4526
Email︰cs@usmarthk.com
Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp︰+852 5989 2641
Join the Community：
uSMART-Facebook-Page
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.